Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function

Wu Renhua

doi:10.13406/j.cnki.cyxb.002878

您当前的位置：

首页 >

文章列表页 >

Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function

更新时间：2024-01-09

- Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function
- Journal of Chongqing Medical University Vol. 46, Issue 8, Pages: 882-887(2021)
- 作者机构：
  
  成都大学附属医院肿瘤科,成都,610081
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002878
  CLC： R730.51
- Published：2021，
扫描看全文
Wu Renhua. Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function. [J]. Journal of Chongqing Medical University 46(8):882-887(2021)
DOI：

Wu Renhua. Efficacy and short-term survival of PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma and its influence on cellular immune function. [J]. Journal of Chongqing Medical University 46(8):882-887(2021) DOI： 10.13406/j.cnki.cyxb.002878.

摘要

目的：观察程序性细胞死亡因子1（programmed cell death 1，PD-1）免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌的疗效，并分析其对细胞免疫功能、短期预后和不良反应的影响。方法：选取成都大学附属医院2018年12月至2020年8月收治的Ⅳ期肺腺癌患者67例，按照治疗方式不同分为对照组（n=33）和联合组（n=34），对照组予以化疗+PD-1抑制剂治疗，联合组予以化疗+PD-1抑制剂+贝伐单抗治疗，比较2组患者近期治疗疗效、治疗前后细胞免疫功能、卡氏功能状态（Karnofsky performance status，KPS）评分变化情况、不良反应及无进展生存期。结果：联合组患者治疗总有效率和疾病控制率分别为29.41%和79.41%，显著高于对照组的9.09%和54.55%（P<0.05）；治疗后，联合组患者CD3+、CD4+、CD4+/CD8+显著高于对照组（P<0.05），CD8+与对照组患者比较无统计学差异（P>0.05）；联合组患者KPS评分增加稳定率为73.53%，显著高于对照组患者的45.45%（P<0.05）；联合组患者骨髓抑制、消化道反应、血液毒性、肝肾功能损害及周围神经毒性不良反应发生率与对照组患者比较，差异无统计学意义（P>0.05）；联合组患者中位无进展生存期为9.73个月，对照组患者中位无进展生存期为6.05个月，差异有统计学意义（P<0.05）。结论： PD-1免疫治疗联合贝伐单抗进行抗血管生成双靶治疗Ⅳ期肺腺癌，可明显提高近期治疗疗效，改善患者免疫功能，提高其生存质量，延长其无进展生存时间。

Abstract

Objective: To observe the efficacy of programmed cell death 1 (PD-1) immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy on stageⅣlung adenocarcinoma

and to analyze its influence on cellular immune function

short-term prognosis and adverse reactions. Methods: A total of 67 patients with stageⅣlung adenocarcinoma admitted to our hospital between December 2018 and August 2020 were selected in this study and they were divided into control group (n=33) and combined group (n=34) according to different treatment methods. Control group were treated with chemotherapy+PD-1 inhibitor

and combined group were treated with chemotherapy+PD-1 inhibitor+bevacizumab. The short-term treatment efficacy

changes of cellular immune function and Karnofsky performance status (KPS) score before and after treatment

adverse reactions and progression-free survival time were compared between the two groups. Results: The total effective rate of treatment and disease control rate of combined group were 29.41%and 79.41%respectively

which were significantly higher than 9.09%and 54.55%of control group (P<0.05). After treatment

the CD3+

CD4+and CD4+/CD8+in combined group were significantly higher than those in control group (P<0.05)

and there was no significant difference in CD8+compared to control group (P>0.05). The increase and stable rate of KPS score of patients in combined group was significantly higher than that in control group (73.53%vs.45.45%) (P<0.05). There were no significant differences in the incidence of adverse reactions such as bone marrow suppression

gastrointestinal reactions

blood toxicity

liver-kidney functional damage and peripheral neurotoxicity in combined group compared with those in control group (P>0.05). The median progression-free survival time were 9.73 months in combined group and were 6.05 months in control group

with significant differences (P<0.05). Conclusion: PD-1 immunotherapy combined with bevacizumab for double-target anti-angiogenic therapy of stageⅣlung adenocarcinoma can significantly enhance the short-term treatment efficacy

improve the immune function

promote the quality of life and prolong the progression-free survival time.

关键词

程序性细胞死亡因子1肿瘤微环境免疫治疗抗血管生成非小细胞肺癌免疫功能生存预后

Keywords

programmed cell death 1tumor microenvironmentimmunotherapyanti-angiogenesisnon-small cell lung cancerimmune functionsurvival prognosis

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

Effects of dendritic cells pulsed with autologous hepatoma cell lysates on the immune function of the postoperative patients with hepatocellular carcinoma

Role of cancer-associated fibroblasts in the proliferation，invasion， and treatment of thyroid cancer

CXCL10/CCL2 signaling pathway mediates the development of cervical cancer in tumor microenvironment

Predictive value of NLR and PLR for outcome after immunotherapy in advanced urothelial carcinoma

Related Author

Wei Kunchen

Wu Junfeng

Tang Hao

GAO Jian

et al

任红

Wu Shasha

Liu Sijia

Related Institution

Beijing Garrison District Haidian 40th Separation Cadre Retreat

Department of Respiratory and Critical Care Medicine,Shanghai Changzheng Hospital

Institute of Hepatology,the Second Affiliated Hospital,Chongqing Medical University

重庆医科大学附属第二医院肝病治疗中心

Rehabilitation Medicine Center,West China Hospital,Sichuan University

⁰